2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. HOXA

HOXA

Homeobox A

Homeobox A (HOXA) is a general term for the genes in cluster A of the Homeobox gene family. HOXA contains the homeobox sequence, which can encode the homeodomain and plays a key regulatory role in processes such as biological embryonic development and cell differentiation. During embryonic development, HOXA can regulate somite differentiation and the positioning of organ primordia, ensuring that all parts of the body develop in the correct pattern and sequence. HOXA is also of great significance for the maintenance of tissue morphology. In addition, HOXA is involved in the differentiation processes of hematopoietic cells, nerve cells, and so on. Abnormalities in HOXA genes are closely related to the occurrence and development of various diseases, including congenital diseases such as hand-foot-genital syndrome and neural tube defects like spina bifida, as well as multiple tumor diseases such as leukemia and breast cancer[1][2].

HOXA Related Products (11):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-153916
    TCRS-417
    		99.13%
    TCRS-417 (T417) is a small-molecular inhibitor for PBX1. TCRS-417 can directly block PBX1-binding to DNA (IC50 = 6.58 μM), and affects PBX1 transcription. TCRS-417 is able to hammer out the stemness traits of Carboplatin (HY-17393)-resistant (CR) cells to revert to a differentiated status through tacking PBX1 signaling cascade. TCRS-417 significantly suppresses self-renewal and proliferation of cancer cells expressing high levels of PBX1. TCRS-417 can decrease the mRNA levels of FOXM1, NEK2, and E2F2 in cancer cell lines. TCRS-417 is selectively toxic against chr1q-amp myeloma and solid tumor cells.
    TCRS-417
  • HY-134258
    MEISi-1
    		Inhibitor 98.16%
    MEISi-1 is a homeodomain inhibitor of small molecule MEIS1 protein. MEISi-1 significantly inhibited the activity of luciferase reporter genes containing MEIS binding sites (TGACAG) and induced self-renewal of mouse and human HSCS in vitro and in vivo. MEISi-1 can be used for research in blood diseases, heart regeneration and cancer.
    MEISi-1
  • HY-134259
    MEISi-2
    		Inhibitor 98.97%
    MEISi-2 is a selective inhibitor of MEIS, a key regulator of hematopoietic stem cell (HSC) self-renewal. MEISi-2 is developed for the research of cardiac injuries, hematopoiesis issues, bone marrow transplantations, and cancer.
    MEISi-2
  • HY-132870
    MEIS-IN-2
    		Inhibitor 99.33%
    MEIS-IN-2 is a myeloid ecotropic viral integration site 1 (MEIS1) inhibitor.
    MEIS-IN-2
  • HY-132869
    MEIS-IN-1
    		Inhibitor 99.32%
    MEIS-IN-1 is a potent myeloid ecotropic viral integration site (MEIS) inhibitor to induce murine and human hematopoietic stem-cell expansion.
    MEIS-IN-1
  • HY-155797
    (S)-Bleximenib
    (S)-Bleximenib (Compound 28) ((S)-JNJ-75276617) is an isoform of Bleximenib (HY-148669). (S)-Bleximenib shows an IC50 greater than 1 μM in the MEIS1 mRNA expression assay. (S)-Bleximenib can be used in the research of acute myeloid leukemia.
    (S)-Bleximenib
  • HY-182945
    IKZF2-degrader 5
    		Inhibitor
    IKZF2-degrader 5 is a highly efficient, highly selective, rapidly acting, and orally active IKZF2 molecular glue degrader. IKZF2-degrader 5 induces IKZF2 degradation via the Cullin-CRBN-dependent pathway. IKZF2-degrader 5 promotes the production of pro-inflammatory IL-2. IKZF2-degrader 5 attenuates the immunosuppressive function of regulatory T cells (Tregs). IKZF2-degrader 5 triggers rapid, significant, and sustained IKZF2 degradation in the spleen and thymus of mice. IKZF2-degrader 5 inhibits tumor growth. IKZF2-degrader 5 can be used for the research of B16F melanoma.
    IKZF2-degrader 5
  • HY-181823
    HOXA1-IN-1
    		Inhibitor
    HOXA1-IN-1 is a HOXA1 inhibitor. HOXA1-IN-1 downregulates HOXA1 protein levels, suppresses its transcriptional activity, and alters the expression of its downstream target genes. HOXA1-IN-1 induces DNA damage and apoptosis in cancer cells. HOXA1-IN-1 exhibits antitumor efficacy in xenograft models of colorectal cancer and triple-negative breast cancer. HOXA1-IN-1 shows synergistic activity in combination with Cisplatin (HY-17394). HOXA1-IN-1 can be used for the research of colorectal cancer and triple-negative breast cancer.
    HOXA1-IN-1
  • HY-178172
    AF9/ENL-DOT1L PPI-IN-1
    		Inhibitor
    AF9/ENL-DOT1L/AF4 PPI-IN-1 is a potent AF9/ENL and histone methyltransferase DOT1L/AF4 protein-protein interactions (PPI) inhibitor. AF9/ENL-DOT1L/AF4 PPI-IN-1 can inhibit the AF9-DOT1L (IC50 = 1.5 μM), AF9-AF4 (IC50 = 1 μM), ENL-AF4 (IC50 = 1.2 μM) interactions. AF9/ENL-DOT1L/AF4 PPI-IN-1 can suppress the expression of Mixed lineage leukemia (MLL) target genes Myc and Meis1 and selectively block the proliferation of MLL-r and several other leukemia cells. AF9/ENL-DOT1L/AF4 PPI-IN-1 exhibits significant antitumor activities in a mouse model of MLL-r leukemia without overt toxicities. AF9/ENL-DOT1L/AF4 PPI-IN-1 can be used for the study of MLL-r leukemia.
    AF9/ENL-DOT1L PPI-IN-1
  • HY-132871
    MEIS-IN-3
    		Inhibitor
    MEIS-IN-3 is a potent myeloid ecotropic viral integration site (MEIS) inhibitor.
    MEIS-IN-3
  • HY-179338
    HPK1-IN-65
    		Inhibitor
    HPK1-IN-65 is a selective and orally active HPK1 inhibitor with an IC50 value of < 5 nM. HPK1-IN-65 inhibits HPK1 kinase activity and displays 1257-fold selectivity over the MAP4K kinase family member GLK. HPK1-IN-65 exhibits an IC50 of 92.3 nM for inhibiting pSLP76 phosphorylation. HPK1-IN-65 demonstrates an EC50 of 398 nM for stimulating IL-2 production. HPK1-IN-65 inhibits TCR-induced phosphorylation of SLP76 at Ser376 in a dose-dependent manner. HPK1-IN-65 can be further utilized for colorectal cancer research.
    HPK1-IN-65